<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182023000200766</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v52n2.104560</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desarrollo de un comprimido de carbonato de litio de liberación prolongada mediante un diseño factorial]]></article-title>
<article-title xml:lang="en"><![CDATA[Development of an extended-release lithium carbonate tablet using a factorial design]]></article-title>
<article-title xml:lang="pt"><![CDATA[Desenvolvimento de um comprimido de carbonato de lítio de liberação prolongada usando um planejamento fatorial]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Almanza]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quirino Barreda]]></surname>
<given-names><![CDATA[Carlos Tomás]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillo Granada]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Adame Martínez]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Guzmán]]></surname>
<given-names><![CDATA[Perla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma Metropolitana  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional Autónoma de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>52</volume>
<numero>2</numero>
<fpage>766</fpage>
<lpage>780</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182023000200766&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182023000200766&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182023000200766&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[ Introducción el carbonato de litio se emplea en el tratamiento del trastorno afectivo bipolar, sin embargo, requiere un control estricto de los niveles séricos debido a que es uno de los fármacos de uso psiquiátrico con un estrecho margen terapéutico. Las formulaciones de carbonato de litio de liberación prolongada tienen la ventaja de proporcionar concentraciones séricas más consistentes, que conducen a menos eventos adversos y mejor apego al tratamiento.  Objetivo fabricar y optimizar mediante un diseño de experimentos factorial un sistema matricial de carbonato de litio con HPMC de baja viscosidad (Methocel® E15LV), para la obtención de comprimidos que cumplan con los criterios de liberación prolongada de la Farmacopea de los Estados Unidos Mexicanos (FEUM).  Métodos se fabricaron los comprimidos mediante granulación vía húmeda y se caracterizaron mediante pruebas farmacopeicas incluyendo estudios de liberación in vitro.  Resultados mediante un diseño 22 se obtuvo una formulación final que cumplió con los requerimientos de porcentaje de fármaco liberado en los tiempos de muestreo establecido por la FEUM. Las propiedades del polímero hidrofílico seleccionado, junto con las variables estudiadas de proporción de polímero (%) y fuerza de compresión permitieron adecuar el perfil de liberación a los niveles establecidos.  Conclusiones se obtuvieron matrices hidrofílicas, con una formulación simple y económica que puede ser empleada en el tratamiento con carbonato de litio mediante liberación prolongada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ Introduction Lithium carbonate is used in the treatment of bipolar affective disorder; however, it requires strict control of serum levels because it is one of the drugs for psychiatric use with a narrow therapeutic margin. Extended-release lithium carbonate formulations have the advantage of providing more consistent serum concentrations, leading to fewer adverse events and better adherence to treatment.  Aim To manufacture and optimize through a factorial design of experiments a lithium carbonate matrix system with a low viscosity HPMC (Methocel® E15LV), to obtain tablets that meet the extended-release criteria of the Pharmacopoeia of the United Mexican States (FEUM).  Methods The tablets were manufactured by wet granulation and characterized by pharmacopoeial tests including in vitro release studies.  Results By means of a design 22 a final formulation was obtained that met the requirement of drug released (%) in the sampling times established by the FEUM. The properties of the selected hydrophilic polymer together with the studied variables of polymer proportion (%) and compressive force allowed the release profile to be adapted to the established levels.  Conclusions Hydrophilic matrices were obtained, with a simple and economical formulation that can be used in the treatment with lithium carbonate by prolonged release.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[ Introdução o carbonato de lítio é utilizado no tratamento do transtorno afetivo bipolar, porém requer controle rigoroso dos níveis séricos por ser um dos fármacos de uso psiquiátrico com estreita margem terapêutica. As formulações de carbonato de lítio de liberação prolongada têm a vantagem de fornecer concentrações séricas mais consistentes, levando a menos eventos adversos e melhor adesão ao tratamento.  Objetivo fabricar e otimizar, por meio de um planejamento fatorial de experimentos, um sistema de matriz de carbonato de lítio com HPMC de baixa viscosidade (Methocel® E15LV), para obter comprimidos que atendam aos critérios de liberação prolongada da Farmacopeia dos Estados Unidos Mexicanos (FEUM).  Métodos os comprimidos foram produzidos por granulação úmida e caracterizados por testes farmacopéicos, incluindo estudos de liberação in vitro.  Resultados utilizando um delineamento 22, obteve-se uma formulação final que atendeu aos requisitos de porcentagem de fármaco liberado nos tempos de amostragem estabelecidos pela FEUM. As propriedades do polímero hidrofílico selecionado, juntamente com as variáveis estudadas de proporção de polímero (%) e força de compressão, permitiram adequar o perfil de liberação aos níveis estabelecidos.  Conclusões foram obtidas matrizes hidrofílicas, com formulação simples e econômica que podem ser utilizadas no tratamento com carbonato de lítio por liberação prolongada.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Carbonato de litio]]></kwd>
<kwd lng="es"><![CDATA[liberación prolongada]]></kwd>
<kwd lng="es"><![CDATA[matriz hidrofílica]]></kwd>
<kwd lng="es"><![CDATA[diseño de experimentos]]></kwd>
<kwd lng="es"><![CDATA[HPMC]]></kwd>
<kwd lng="en"><![CDATA[Lithium carbonate]]></kwd>
<kwd lng="en"><![CDATA[extended release]]></kwd>
<kwd lng="en"><![CDATA[hydrophilic matrix]]></kwd>
<kwd lng="en"><![CDATA[design of experiments]]></kwd>
<kwd lng="en"><![CDATA[HPMC]]></kwd>
<kwd lng="pt"><![CDATA[Carbonato de lítio]]></kwd>
<kwd lng="pt"><![CDATA[liberação sustentada]]></kwd>
<kwd lng="pt"><![CDATA[matriz hidrofílica]]></kwd>
<kwd lng="pt"><![CDATA[planejamento de experimentos]]></kwd>
<kwd lng="pt"><![CDATA[HPMC]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moncrieff]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El litio y otros fármacos usados para el trastorno maníaco-depresivo]]></article-title>
<source><![CDATA[Revista de la Asociación Española de Neuropsiquiatría]]></source>
<year>2018</year>
<volume>38</volume>
<numero>133</numero>
<issue>133</issue>
<page-range>283-99</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Alzate-Carvajal]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata-Castañeda]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil de utilización del carbonato de litio en pacientes con trastorno afectivo bipolar en 25 ciudades de Colombia]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2017</year>
<volume>37</volume>
<page-range>43-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girardi]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Brugnoli]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Manfredi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sani]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lithium in bipolar disorder: Optimizing therapy using prolonged-release formulations]]></article-title>
<source><![CDATA[Drugs in R &amp; D]]></source>
<year>2016</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shinde]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kadam]]></surname>
<given-names><![CDATA[P.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Biradar]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tolsarwad]]></surname>
<given-names><![CDATA[G.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and evaluation of sustained release matrix tablet of lithium carbonate using hydroxypropyl methylcellulose]]></article-title>
<source><![CDATA[Innovations in Pharmaceuticals and Pharmacotherapy]]></source>
<year>2020</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>83-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Farmacopea de los Estados Unidos Mexicanos]]></source>
<year>2018</year>
<edition>12a ed.</edition>
<publisher-loc><![CDATA[México D.F. ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko&#353;ir]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ojster&#353;ek]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Baumgartner]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Vre&#269;er]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A study of critical functionality-related characteristics of HPMC for sustained-release tablets]]></article-title>
<source><![CDATA[Pharmaceutical Development and Technology]]></source>
<year>2018</year>
<volume>23</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>865-73</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hiremath]]></surname>
<given-names><![CDATA[P.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Saha]]></surname>
<given-names><![CDATA[R.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlled release hydrophilic matrix tablet formulations of isoniazid: Design and in vitro studies]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2008</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1171-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qazi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation development and evaluation of Diltiazem HCl sustained release matrix tablets using HPMC]]></article-title>
<source><![CDATA[Pakistan Journal of Pharmaceutical Sciences]]></source>
<year>2013</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>653-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruschi]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mathematical models of drug release]]></article-title>
<source><![CDATA[Strategies to modify the drug release from pharmaceutical systems]]></source>
<year>2015</year>
<publisher-name><![CDATA[Woodhead Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almanza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Barreda]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Tomás]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto de la hidroxipropilmetilcelulosa (HPMC) en la liberación de un fármaco iónico]]></article-title>
<source><![CDATA[Revista Mexicana de Ciencias Farmacéuticas]]></source>
<year>2016</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-61</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Chudasama]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nivsarkar]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Vasu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Shishoo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Push-pull osmotic pump for zero order delivery of lithium carbonate : Development and in vitro characterization]]></article-title>
<source><![CDATA[Pharmaceutical Development and Technology]]></source>
<year>2012</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>375-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
